Fennec Pharmaceuticals (FRX) Stock Chart & Stock Price History C$12.70 +1.30 (+11.40%) As of 03:59 PM Eastern Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesBuy This Stock Fennec Pharmaceuticals Stock Price Performance The Fennec Pharmaceuticals (FRX) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 47.33%, with a year-to-date return of 43.18%. In the past month, the stock has increased 4.96%, reflecting recent market activity. As of the latest close, Fennec Pharmaceuticals traded at C$11.40 with a market cap of C$219.85 million and volume of 528 shares. Five years ago, the stock traded at C$8.18, representing a 55.26% increase over that period. At the time, it had a market cap of C$301.74 million and a volume of 21,964 shares. Receive FRX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+15.45%1 Month Performance+4.96%3 Month Performance+46.65%Year-To-Date Performance+43.18%1 Year Performance+47.33%5 Year Performance+55.26% FRX Stock Chart for Tuesday, August, 12, 2025 FRX Chart by TradingView Fennec Pharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/11/2025C$11.40C$11.40C$11.40C$11.10528 shsC$219.85 million08/08/2025C$11.00C$11.40+3.64%C$11.40C$11.10528 shsC$219.85 million08/07/2025C$11.15C$11.00-1.35%C$11.55C$11.00394 shsC$212.13 million08/06/2025C$11.01C$11.15+1.27%C$11.15C$11.15100 shsC$215.02 million08/05/2025C$11.01C$11.01C$11.01C$10.91300 shsC$212.32 million08/04/2025C$11.01C$11.01C$11.01C$10.91300 shsC$212.32 million08/01/2025C$11.40C$11.01-3.42%C$11.01C$10.91300 shsC$212.32 million07/31/2025C$11.72C$11.40-2.73%C$11.45C$11.40700 shsC$219.85 million07/30/2025C$11.72C$11.72C$11.72C$11.72106 shsC$226.02 million07/29/2025C$11.72C$11.72C$11.72C$11.72106 shsC$226.02 million Get the Latest News and Ratings for FRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 07/28/2025C$11.99C$11.72-2.25%C$11.72C$11.72106 shsC$226.02 million07/25/2025C$11.99C$11.99C$12.07C$11.97968 shsC$231.22 million07/24/2025C$11.74C$11.99+2.13%C$12.07C$11.97968 shsC$231.22 million07/23/2025C$11.99C$11.74-2.09%C$11.74C$11.74320 shsC$226.40 million07/22/2025C$11.51C$11.99+4.17%C$11.99C$11.991,504 shsC$231.22 million07/21/2025C$11.64C$11.51-1.12%C$11.55C$11.51300 shsC$221.97 million07/18/2025C$11.98C$11.64-2.84%C$11.84C$11.64200 shsC$224.47 million07/17/2025C$11.67C$11.98+2.66%C$11.98C$11.98144 shsC$231.03 million07/16/2025C$11.67C$11.67C$11.67C$11.67100 shsC$225.05 million07/15/2025C$11.92C$11.67-2.10%C$11.67C$11.67100 shsC$225.05 million07/14/2025C$12.10C$11.92-1.49%C$12.05C$11.92202 shsC$229.87 million07/11/2025C$12.50C$12.10-3.20%C$12.99C$12.101,582 shsC$233.35 million Related Companies SLS Stock Chart CRON Stock Chart TLRY Stock Chart AIM Stock Chart ITH Stock Chart GXE Stock Chart CRDL Stock Chart GPH Stock Chart MDNA Stock Chart EQ Stock Chart Receive FRX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (TSE:FRX) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredElon Musk: “Nothing happens without this…”Lithium has fueled the EV boom, but another resource is even more critical. Without it, over 20 million electr...Behind the Markets | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fennec Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access